Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose and multiple-ascending dose clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN:
- Septerna price target raised to $38 from $34 at JPMorgan
- Septerna, Inc. (SEPN) Q4 Earnings Cheat Sheet
- Septerna price target raised to $35 from $34 at Truist
- Septerna files automatic mixed securities shelf
- Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating